查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1668101

抗凝血酶市場 - 全球產業規模、佔有率、趨勢、機會和預測，按用途、來源、類型、地區和競爭細分，2020-2030 年

Antithrombin Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Usage, By Source, By Type, By Region and Competition, 2020-2030F
出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球抗凝血酶市場價值為 7.8203 億美元，預計到 2030 年將達到 10.6623 億美元，預測期內的複合年成長率為 5.26%。抗凝血酶市場涵蓋製藥和生物技術行業生產和分銷抗凝血酶產品的努力。抗凝血酶是血液中天然存在的蛋白質，在調節血液凝固中扮演至關重要的角色。當抗凝血酶水平失調時，會導致血栓栓塞性疾病，如深部靜脈栓塞 (DVT)、肺栓塞 (PE) 和瀰漫性血管內凝血 (DIC)。因此，抗凝血酶產品對於預防和治療這些疾病都至關重要。

市場概況
預測期 2026-2030
2024 年市場規模 7.8203億美元
2030 年市場規模 10.6623億美元
2025-2030 年複合年成長率 5.26%
成長最快的領域 療法
最大的市場 亞太

主要市場促進因素

血栓性疾病盛行率上升

主要市場挑戰

認知和診斷有限

主要市場趨勢

擴大治療適應症

目錄

第 1 章：產品概述

第 2 章：研究方法

第 3 章：執行摘要

第 4 章：顧客之聲

第5章：全球抗凝血酶市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按用途（治療、診斷、研究、其他）
    • 依來源分類（人類、重組羊奶、其他）
    • 依類型（抗凝血藥、抗血小板藥、溶栓藥）
    • 按地區
    • 按公司分類（2024）
  • 市場地圖

第 6 章：北美抗凝血酶市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美：國家分析
    • 加拿大
    • 墨西哥

第 7 章：歐洲抗凝血酶市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲：國家分析
    • 英國
    • 義大利
    • 法國
    • 西班牙

第 8 章：亞太地區抗凝血酶市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區：國家分析
    • 印度
    • 日本
    • 韓國
    • 澳洲

第 9 章：南美洲抗凝血酶市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲：國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章：中東和非洲抗凝血酶市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章：市場動態

  • 驅動程式
  • 挑戰

第 12 章：市場趨勢與發展

  • 合併與收購（如有）
  • 產品發布（如果有）
  • 最新動態

第 13 章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 14 章：競爭格局

  • Grifols, SA
  • Takeda Pharmaceutical Company Limited
  • Octapharma Brasil Ltda.
  • LFB USA, Inc.
  • Endpoint Health, Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc
  • BioCare, Inc.
  • F. Hoffmann-La Roche Ltd
  • Kedrion SpA

第 15 章：策略建議

第16章 關於出版商,免責事項

簡介目錄
Product Code: 18841

The global antithrombin market was valued at USD 782.03 million in 2024 and is projected to reach USD 1,066.23 million by 2030, growing at a CAGR of 5.26% during the forecast period. The antithrombin market encompasses the pharmaceutical and biotechnology industries' efforts to produce and distribute antithrombin products. Antithrombin, a naturally occurring protein in the blood, plays a crucial role in regulating blood clotting. When antithrombin levels are dysfunctional, it can lead to thromboembolic disorders such as deep vein thrombosis (DVT), pulmonary embolism (PE), and disseminated intravascular coagulation (DIC). Antithrombin products are therefore critical for both the prevention and treatment of these conditions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 782.03 Million
Market Size 2030USD 1066.23 Million
CAGR 2025-20305.26%
Fastest Growing SegmentTherapeutics
Largest MarketAsia-Pacific

Key Market Drivers

Rising Prevalence of Thrombotic Disorders

Thrombotic disorders, marked by the formation of blood clots within the circulatory system, are a significant global health threat. As the incidence of these conditions rises, so does the demand for effective treatments. Antithrombin products are becoming essential in the management and prevention of thrombotic events.

Thrombotic disorders include DVT, PE, stroke, and DIC, which can lead to severe complications, such as organ damage and death. According to the World Health Organization (WHO), thrombosis is a major contributor to global morbidity and mortality. In the U.S., the Centers for Disease Control and Prevention reports that venous thromboembolism (VTE) affects up to 900,000 people annually, with 60,000 to 100,000 deaths attributed to the condition each year. Additionally, many individuals experience long-term complications. Risk factors for thrombotic events include advanced age, sedentary lifestyles, obesity, diabetes, cancer, cardiovascular disease, and genetic predisposition. Major surgeries, particularly orthopedic, cardiovascular, and gynecological procedures, also increase the risk of clot formation. As a result, antithrombin products are often used prophylactically in these high-risk scenarios.

Antithrombin, a natural protein in the bloodstream, regulates the clotting process by inhibiting key clotting factors, including thrombin and factor Xa. When antithrombin levels are deficient or impaired, the likelihood of clot formation increases. Consequently, the growing prevalence of thrombotic disorders is driving increased demand for antithrombin products, both for prevention and treatment. The rise in surgical procedures and the need for antithrombin therapy for patients experiencing thrombotic events further contribute to market growth. The increasing need for advanced antithrombin therapies, such as recombinant products, is also fueling research and development in the market.

Key Market Challenges

Limited Awareness and Diagnosis

One of the significant challenges facing the antithrombin market is the lack of awareness about thrombotic disorders such as DVT and PE. These conditions often present with subtle or non-specific symptoms, and many individuals are unaware of their risk factors. Common symptoms, such as leg pain, swelling, or difficulty breathing, are often overlooked or misattributed to less severe conditions, delaying diagnosis and treatment. This lack of awareness hinders timely medical intervention, reducing the demand for antithrombin therapies.

Without early detection, thrombotic disorders can lead to severe health consequences, including organ damage, stroke, or death. Therefore, raising awareness of thrombotic disorders, their symptoms, and the importance of early diagnosis is crucial for improving patient outcomes and expanding the market for antithrombin products.

Key Market Trends

Expanding Therapeutic Indications

Historically, antithrombin therapies have been primarily associated with the treatment of thrombotic disorders. However, ongoing research and clinical trials are expanding the potential therapeutic applications of these treatments. For example, antithrombin products are being explored for their role in sepsis, a severe systemic response to infection where blood clotting contributes to organ failure. By targeting the coagulation pathway, antithrombin therapies may help manage sepsis-induced coagulopathy, improving patient outcomes.

In February 2022, Grifols partnered with Endpoint Health, Inc. to develop a therapy for sepsis using Antithrombin III (AT-III). This collaboration aims to leverage Grifols' expertise in plasma-protein therapies, with the company serving as the exclusive provider of AT-III.

Antithrombin products are also being investigated for their potential benefits in liver diseases such as cirrhosis and acute liver failure, where blood clotting factors play a key role in disease progression. Additionally, these therapies are being studied as adjuncts to cancer treatments, as tumors can cause coagulation system alterations, increasing the risk of thrombotic events in cancer patients.

The expansion of therapeutic indications presents new opportunities for the antithrombin market. As antithrombin therapies gain recognition in treating a broader range of conditions, such as sepsis, liver diseases, and cancer, the demand for these products is expected to increase, opening new market avenues and enhancing patient outcomes in complex, life-threatening diseases.

Key Market Players

  • Grifols, S.A.
  • Takeda Pharmaceutical Company Limited
  • Octapharma Brasil Ltda.
  • LFB USA, Inc.
  • Endpoint Health, Inc.
  • Siemens Healthineers AG
  • Thermo Fisher Scientific Inc
  • BioCare, Inc.
  • F. Hoffmann-La Roche Ltd
  • Kedrion S.p.A

Report Scope:

In this report, the Global Antithrombin Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Antithrombin Market, By Usage:

  • Therapeutics
  • Diagnostics
  • Research
  • Others

Antithrombin Market, By Source:

  • Human
  • Recombinant Goat Milk
  • Others

Antithrombin Market, By Type:

  • Anticoagulant
  • Antiplatelet
  • Thrombolytic Drugs

Antithrombin Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • Germany
    • United Kingdom
    • France
    • Italy
    • Spain
  • Asia-Pacific
    • China
    • Japan
    • India
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East & Africa
    • South Africa
    • Saudi Arabia

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Antithrombin Market.

Available Customizations:

Global Antithrombin market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validations
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Antithrombin Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Usage (Therapeutics, Diagnostics, Research, Others)
    • 5.2.2. By Source (Human, Recombinant Goat Milk, Others)
    • 5.2.3. By Type (Anticoagulant, Antiplatelet, Thrombolytic Drugs)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. North America Antithrombin Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Usage
    • 6.2.2. By Source
    • 6.2.3. By Type
    • 6.2.4. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Antithrombin Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Usage
        • 6.3.1.2.2. By Source
        • 6.3.1.2.3. By Type
    • 6.3.2. Canada Antithrombin Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Usage
        • 6.3.2.2.2. By Source
        • 6.3.2.2.3. By Type
    • 6.3.3. Mexico Antithrombin Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Usage
        • 6.3.3.2.2. By Source
        • 6.3.3.2.3. By Type

7. Europe Antithrombin Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Usage
    • 7.2.2. By Source
    • 7.2.3. By Type
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Antithrombin Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Usage
        • 7.3.1.2.2. By Source
        • 7.3.1.2.3. By Type
    • 7.3.2. United Kingdom Antithrombin Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Usage
        • 7.3.2.2.2. By Source
        • 7.3.2.2.3. By Type
    • 7.3.3. Italy Antithrombin Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Usage
        • 7.3.3.2.2. By Source
        • 7.3.3.2.3. By Type
    • 7.3.4. France Antithrombin Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Usage
        • 7.3.4.2.2. By Source
        • 7.3.4.2.3. By Type
    • 7.3.5. Spain Antithrombin Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Usage
        • 7.3.5.2.2. By Source
        • 7.3.5.2.3. By Type

8. Asia-Pacific Antithrombin Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Usage
    • 8.2.2. By Source
    • 8.2.3. By Type
    • 8.2.4. By Country
  • 8.3. Asia-Pacific: Country Analysis
    • 8.3.1. China Antithrombin Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Usage
        • 8.3.1.2.2. By Source
        • 8.3.1.2.3. By Type
    • 8.3.2. India Antithrombin Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Usage
        • 8.3.2.2.2. By Source
        • 8.3.2.2.3. By Type
    • 8.3.3. Japan Antithrombin Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Usage
        • 8.3.3.2.2. By Source
        • 8.3.3.2.3. By Type
    • 8.3.4. South Korea Antithrombin Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Usage
        • 8.3.4.2.2. By Source
        • 8.3.4.2.3. By Type
    • 8.3.5. Australia Antithrombin Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Usage
        • 8.3.5.2.2. By Source
        • 8.3.5.2.3. By Type

9. South America Antithrombin Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Usage
    • 9.2.2. By Source
    • 9.2.3. By Type
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Antithrombin Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Usage
        • 9.3.1.2.2. By Source
        • 9.3.1.2.3. By Type
    • 9.3.2. Argentina Antithrombin Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Usage
        • 9.3.2.2.2. By Source
        • 9.3.2.2.3. By Type
    • 9.3.3. Colombia Antithrombin Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Usage
        • 9.3.3.2.2. By Source
        • 9.3.3.2.3. By Type

10. Middle East and Africa Antithrombin Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Usage
    • 10.2.2. By Source
    • 10.2.3. By Type
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Antithrombin Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Usage
        • 10.3.1.2.2. By Source
        • 10.3.1.2.3. By Type
    • 10.3.2. Saudi Arabia Antithrombin Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Usage
        • 10.3.2.2.2. By Source
        • 10.3.2.2.3. By Type
    • 10.3.3. UAE Antithrombin Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Usage
        • 10.3.3.2.2. By Source
        • 10.3.3.2.3. By Type

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Products

14. Competitive Landscape

  • 14.1. Grifols, S.A.
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Financials (As Reported)
    • 14.1.5. Recent Developments
    • 14.1.6. Key Personnel Details
    • 14.1.7. SWOT Analysis
  • 14.2. Takeda Pharmaceutical Company Limited
  • 14.3. Octapharma Brasil Ltda.
  • 14.4. LFB USA, Inc.
  • 14.5. Endpoint Health, Inc.
  • 14.6. Siemens Healthineers AG
  • 14.7. Thermo Fisher Scientific Inc
  • 14.8. BioCare, Inc.
  • 14.9. F. Hoffmann-La Roche Ltd
  • 14.10. Kedrion S.p.A

15. Strategic Recommendations

16. About Us & Disclaimer